Literature DB >> 11710450

Lipoatrophy associated with glatiramer acetate injections for the treatment of multiple sclerosis.

L Hwang1, I Orengo.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11710450

Source DB:  PubMed          Journal:  Cutis        ISSN: 0011-4162


× No keyword cloud information.
  3 in total

1.  Lipoatrophy: a non-reversible complication of subcutaneous interferon-beta 1a treatment of multiple sclerosis.

Authors:  Antonie Giaever Beiske; Kjell-Morten Myhr
Journal:  J Neurol       Date:  2006-03-06       Impact factor: 4.849

Review 2.  Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.

Authors:  Dene Simpson; Stuart Noble; Caroline Perry
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 3.  US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles.

Authors:  Steven L Galetta; Clyde Markowitz
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.